Early Lyme borreliosis sera with significant titers of anti-outer surface protein C (OspC) borreliacidal antibodies were identified. Human anti-OspC borreliacidal antibodies could be either IgM or IgG. Significant concentrations of borreliacidal activity were detected after vaccination of mice with OspC. Detection of anti-OspC borreliacidal activity was dependent on surface expression of OspC by Borrelia burgdorferi isolate 50772. The ability of OspC to induce borreliacidal antibodies in vivo and after vaccination offers another possible explanation for the ability of vaccination with OspC to protect against infection with B. burgdorferi. Furthermore, detection of anti-OspC borreliacidal antibodies, especially IgM antibodies, in early Lyme borreliosis sera provides additional evidence that borreliacidal antibody detection may be useful for the serodiagnosis of early Lyme borreliosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/515382 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single-domain antibodies reveal unique borrelicidal epitopes on the Lyme disease vaccine antigen, outer surface protein A (OspA).
Infect Immun
April 2024
Division of Infectious Diseases, New York State Department of Health, Wadsworth Center, Albany, New York, USA.
Article Synopsis
- Camelid-derived single-domain antibodies (VHs) are effective in studying diverse surface proteins' antigenic properties, specifically in Lyme disease research.
- Two alpacas were immunized to create a phage-displayed VH library against an important Lyme vaccine antigen, outer surface protein A (OspA), leading to the identification of 21 unique VHs.
- The study highlights that these VHs exhibit different reactivities across various OspA serotypes, indicating the need for considering unique epitopes when developing multivalent Lyme disease vaccines.
A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted in mice.
Res Sq
July 2023
Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA.
Lyme disease (LD) is the most prevalent vector borne disease in North America and Europe and its geographic range continues to expand. Strategies for disease control are necessary to effectively reduce incidence of LD including development of safe vaccines for human use. Parainfluenza virus 5 (PIV5) vector has an excellent safety record in animals and PIV5-vectored COVID-19 and RSV vaccines are currently under clinical development.
View Article and Find Full Text PDFStructure of a transmission blocking antibody in complex with Outer surface protein A from the Lyme disease spirochete, Borreliella burgdorferi.
Proteins
November 2023
Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
319-44 is a human monoclonal antibody capable of passively protecting mice against tick-mediated infection with Borreliella burgdorferi, the bacterial genospecies responsible for Lyme disease in North America. In vitro, 319-44 has complement-dependent borreliacidal activity and spirochete agglutinating properties. Here, we report the 2.
View Article and Find Full Text PDFDNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous needle challenge in mice.
Front Immunol
April 2023
Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.
Introduction: The incidence of Lyme disease (LD) in Canada and the United States has risen over the last decade, nearing 480,000 cases each year. sensu lato, the causative agent of LD, is transmitted to humans through the bite of an infected tick, resulting in flu-like symptoms and often a characteristic bull's-eye rash. In more severe cases, disseminated bacterial infection can cause arthritis, carditis and neurological impairments.
View Article and Find Full Text PDFHuman B Cell Epitope Map of the Lyme Disease Vaccine Antigen, OspA.
ACS Infect Dis
December 2022
Department of Chemistry, University of Kansas, Lawrence, Kansas66045, United States.
Article Synopsis
- - The Lyme disease vaccine approved in the U.S. targeted the outer surface protein A (OspA) of the bacteria causing Lyme disease, which has a specific structure made up of β-strands and α-helices.
- - Clinical trials showed that the effectiveness of the vaccine was linked to the antibody response against a particular region of OspA recognized by a mouse monoclonal antibody, but the full human antibody response remains unclear.
- - Research using hydrogen exchange-mass spectrometry identified key human antibodies and their respective binding sites on OspA, revealing three main regions (or bins) that could help inform the development of future vaccines and provide insight into immune response against Lyme disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!